If you require special assistance to attend this event, please call Kim Page at (859) 218-0340.
An Equal Opportunity University.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Remedica Medical Education and Publishing, Ltd.. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.The University of Kentucky College of Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
- Patient care
- Medical knowledge
- Practice-based learning and improvement
UK Healthcare CECentral certifies this activity for 2.00 hours of participation.
Upon completion of this education activity, participants will be able to:
- Demonstrate an understanding of key recommendations made by international clinical practice guidelines on the treatment of patients with mCRPC in the context of routine local practice
- Interpret the latest data supporting the use of the novel agents for mCRPC
- Identify how to integrate best practices and evidence-based data to determine the optimal, individualized sequence of new agents in mCRPC
- Explain the rationale for the current combination studies using new agents for patients with mCRPC
- Evaluate the differences among new agents for mCRPC in order to make evidence-based, individualized treatment decisions for patients
Physicians treating patients with castration-resistant prostate cancer (CRPC).